I

addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

#### **Amendments**

In the Claims:

# Please substitute the following claim 1 for the pending claim 1:

1. (Once amended) A compound having the Formula I:

R<sub>5</sub> R<sub>5</sub> Het

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein

X is one of O, S, NR<sub>9</sub>, or CH<sub>2</sub>, where R<sub>9</sub> is/hydrogen or C<sub>1</sub>-C<sub>10</sub> alkyl;

Het is a heteroaryl selected from the group consisting of

 $R_1$  is selected from the group consisting of hydrogen, optionally substituted alkyl, heteroaryl optionally substituted with one or more groups independently selected from the group consisting of halo, halo  $(C_{1-6})$  alkyl, hydroxy  $(C_{1-6})$  alkyl, amino  $(C_{1-6})$  alkyl, hydroxy, nitro,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, aminocarbonyl, carbamoyloxy,  $C_{1-6}$  alkylsulfonylamino,  $C_{1-6}$  acyl and amino,  $C(O)R_{10}$ ,  $CH_2C(O)R_{10}$ ,  $S(O)R_{10}$ , and  $SO_2R_{10}$ ;

R<sub>2</sub> and R<sub>3</sub> are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cyano, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkylthio,

Sub 300 alkylsulfinyl, alkylsulfonyl, carboxyalkyl, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, aralkylcarbonylamino, alkylcarbonyl, aminosulfonyl, alkylaminosulfonyl, and alkylsulfonyl;

R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, and R<sub>8</sub> are independently selected from the group consisting of hydrogen, halo, haloalkyl, alkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, alkoxyalkyl, nitro, amino, ureido, cyano, acylamino, amide, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido and alkylthiol;

R<sub>10</sub> is selected from the group consisting of amino, alkyl, alkenyl, alkynyl, OR<sub>11</sub>, alkylamino, dialkylamino, alkenylamino, dialkylaminoalkenyl, cycloalkyl, heterocycle, heteroaryl, aryl, aralkyl, arylalkenyl, arylalkynyl, and cycloalkylalkylamino;

R<sub>11</sub> is selected from the group consisting of hydrogen, optionally substituted alkyl, and an alkalimetal; and

provided that:

- 1) when Het is (ii), and X is O, then R<sub>10</sub> is not alkyl, aralkyl, aryl or OR<sub>11</sub>;
- 2) when Het is (i) or (ii), then X is not NR<sub>9</sub>;
- 3) when Het is (iii), then X is not CH2; and
- 4) when Het is (iii), and X is O, then R<sub>10</sub> is not OR<sub>11</sub>.

# Please substitute the following claim 10 for the pending claim 10:

10. (Once Amended) A compound of claim 9, wherein:


R<sub>5</sub> and R<sub>6</sub> are each hydrogen;

R<sub>3</sub> and R<sub>2</sub> are both H; and

 $R_7$  and  $R_8$  are selected from the group consisting of hydrogen, halo, halo( $C_1$ - $C_6$ )alkyl,  $C_1$ - $C_6$  alkyl, hydroxy( $C_1$ - $C_6$ )alkyl, amino( $C_1$ - $C_6$ )alkyl, alkoxy( $C_1$ - $C_6$ )alkyl, nitro, amino,  $C_1$ - $C_6$  acylamino, amide, hydroxy, thiol,  $C_1$ - $C_6$  acyloxy,  $C_1$ - $C_6$  alkoxy, carboxy, carbonylamido and  $C_1$ - $C_6$  alkylthiol.

Please substitute the following claim 15 for the pending claim 15:





 $R_1$  is  $C(O)R_{10}$ ,  $CH_2C(O)R_{10}$ , or  $SO_2R_{10}$ ;

X is O or S;

R<sub>10</sub> is amino, optionally substituted C<sub>1</sub>-C<sub>6</sub> alkyl, or a heterocycle selected from the group consisting of N-morpholinyl, N-pyrrolidinyl and N-piperazinyl;

R<sub>2</sub>, and R<sub>3</sub> are independently hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylthio or C<sub>1</sub>-C<sub>6</sub> alkylsulfinyl,

R<sub>5</sub> and R<sub>6</sub> are as defined in claim 1, and

 $R_7$  and  $R_8$  are independently selected from the group consisting of hydrogen, halo, halo( $C_1$ - $C_6$ )alkyl,  $C_1$ - $C_6$  alkyl, hydroxy( $C_1$ - $C_6$ )alkyl, amino( $C_1$ - $C_6$ )alkyl, carboxy( $C_1$ - $C_6$ )alkyl, alkoxy( $C_1$ - $C_6$ )alkyl, nitro, amino,  $C_1$ - $C_6$  acylamino, amide, hydroxy, thiol,  $C_1$ - $C_6$  acyloxy,  $C_1$ - $C_6$  alkoxy, carboxy, carbonylamido and  $C_1$ - $C_6$  alkylthiol.

#### Please substitute the following claim 16 for the pending claim 16:

### 16. (Once Amended) A compound of Formula I:

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein

X is O or S;

Het is a heteroaryl selected from the group consisting of

 $R_1$  is  $C(O)R_{10}$ ,  $CH_2C(O)R_{10}$ , or  $SO_2R_{10}$  wherein  $R_{10}$  is amino, alkyl, N-morpholinyl, N-pyrrolidinyl or N-piperazinyl, all of which are optionally substituted;

5/1/2

R<sub>2</sub> and R<sub>3</sub> are independently hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylthio or C<sub>1</sub>-C<sub>6</sub> alkylsulfinyl;

 $R_5$ ,  $R_6$ ,  $R_7$  and  $R_8$  are independently selected from the group consisting of hydrogen, halo, halo( $C_1$ - $C_6$ )alkyl,  $C_1$ - $C_6$  alkyl, hydroxy( $C_1$ - $C_6$ )alkyl, amino( $C_1$ - $C_6$ )alkyl, carboxy( $C_1$ - $C_6$ )alkyl, alkoxy( $C_1$ - $C_6$ )alkyl, nitro, amino,  $C_1$ - $C_6$  acylamino, amide, hydroxy, thiol,  $C_1$ - $C_6$  acyloxy,  $C_1$ - $C_6$  alkoxy, carboxy, carbonylamido and  $C_1$ - $C_6$  alkylthiol;

provided that:

- 1) when Het is (ii), and X is O, then  $R_{10}$  is not alkyl, aralkyl, aryl or  $OR_{11}$ ; and
- 2) when Het is (iii), and X is O, then R<sub>10</sub> is not OR<sub>11</sub>.

### Please substitute the following claim 22 for the pending claim 22:

# 22. (Once Amended) A compound of Formula I:

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein

X is O or S;

Het is a heteroaryl selected from the group consisting of


$$-N \longrightarrow R_{2} \qquad -N \longrightarrow R_{2} \qquad -N \longrightarrow R_{3} \qquad -N \longrightarrow R_{1} \qquad -N \longrightarrow R_{1} \qquad -N \longrightarrow R_{2} \qquad -N \longrightarrow R_{3} \qquad (iii) \qquad (iv)$$

 $R_1$  is  $C(O)R_{10}$ , wherein  $R_{10}$  is amino, N-morpholinyl, N-pyrrolidinyl or N-piperazinyl, all of which are optionally substituted

R<sub>2</sub> and R<sub>3</sub> are independently hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylthio or C<sub>1</sub>-C<sub>6</sub> alkylsulfinyl;

 $R_5$ ,  $R_6$ ,  $R_7$  and  $R_8$  are independently selected from the group consisting of hydrogen, halo, halo( $C_1$ - $C_6$ )alkyl,  $C_1$ - $C_6$  alkyl, hydroxy( $C_1$ - $C_6$ )alkyl, amino( $C_1$ - $C_6$ )alkyl,

Who was



carboxy( $C_1$ - $C_6$ )alkyl, alkoxy( $C_1$ - $C_6$ )alkyl, nitro, amino,  $C_1$ - $C_6$  acylamino, amide, hydroxy, thiol,  $C_1$ - $C_6$  acyloxy,  $C_1$ - $C_6$  alkoxy, carboxy, carboxylamido and  $C_1$ - $C_6$  alkylthiol.

#### Please insert the following claims 24-27:

24. (New) A compound of claim 15, wherein R<sub>5</sub> and R<sub>6</sub> are both hydrogen.

25. (New) A compound having the Formula I:

 $R_8$   $R_8$   $R_6$   $R_8$   $R_6$ 

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein X is NR<sub>9</sub>C(O) or C(O)NR<sub>9</sub>, where R<sub>9</sub> is hydrogen or C<sub>1</sub>-C<sub>10</sub> alkyl; Het is a heteroaryl selected from the group consisting of

$$-N \longrightarrow R_{2} \qquad -N \longrightarrow R_{2} \qquad -N \longrightarrow R_{3} \qquad -N \longrightarrow R_{1} \qquad -N \longrightarrow R_{1} \qquad -N \longrightarrow R_{1} \qquad -N \longrightarrow R_{1} \qquad -N \longrightarrow R_{2} \qquad -N \longrightarrow R_{3} \qquad (iii) \qquad (iv)$$

R<sub>1</sub> is SO<sub>2</sub>R<sub>10</sub>;

R<sub>2</sub> and R<sub>3</sub> are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cyano, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkylthio, alkylsulfinyl, alkylsulfinyl, carboxyalkyl, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, alkylcarbonyl, aminosulfonyl, alkylaminosulfonyl, and alkylsulfonyl;

Sub

Sub

R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, and R<sub>8</sub> are independently selected from the group consisting of hydrogen, halo, haloalkyl, alkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, alkoxyalkyl, nitro, amino, ureido, cyano, acylamino, amide, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido and alkylthiol;

R<sub>10</sub> is selected from the group consisting of amino, alkyl, alkenyl, alkynyl, OR<sub>11</sub>, alkylamino, dialkylamino, alkenylamino, dialkylaminoalkenyl, cycloalkyl, heterocycle, heteroaryl, aryl, aralkyl, arylalkenyl, arylalkynyl, and cycloalkylalkylamino; and

R<sub>11</sub> is selected from the group consisting of hydrogen, optionally substituted alkyl, and an alkalimetal.

26. (New) A compound having the Formula I:

$$R_8$$
 $R_6$ 
 $R_6$ 
 $R_6$ 
Het

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein

X is one of O, S, NR<sub>9</sub>, CH<sub>2</sub>, NR<sub>9</sub>C(O), or C(O)NR<sub>9</sub>, where R<sub>9</sub> is hydrogen or  $C_1$ - $C_{10}$  alkyl;

Het is a heteroaryl selected from the group consisting of

$$-\underset{R_{3}}{\overset{N}{\bigvee}}\underset{(ii)}{\overset{R_{1}}{\bigvee}}\underset{(iii)}{\overset{R_{1}}{\bigvee}}\underset{R_{3}}{\overset{N}{\bigvee}}\underset{(iiii)}{\overset{R_{1}}{\bigvee}}\underset{(iv)}{\overset{N}{\bigvee}}\underset{(iv)}{\overset{R_{1}}{\bigvee}}$$

 $R_1$  is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted heteroaryl,  $C(O)R_{10}$ ,  $CH_2C(O)R_{10}$ ,  $S(O)R_{10}$ , and  $SO_2R_{10}$ ;

R<sub>2</sub> and R<sub>3</sub> are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cyano, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, carboxyalkyl, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, aralkylcarbonylamino, alkylcarbonyl, aminosulfonyl,

alkylaminosulfonyl, and alkylsulfonyl;

R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, and R<sub>8</sub> are independently selected from the group consisting of hydrogen, halo, haloalkyl, alkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, alkoxyalkyl, nitro, amino, ureido, cyano, acylamino, amide, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido and alkylthiol;

R<sub>10</sub> is selected from the group consisting of amino, alkyl, alkenyl, alkynyl, OR<sub>11</sub>, alkylamino, dialkylamino, alkenylamino, dialkylaminoalkenyl, cycloalkyl, heterocycle, heteroaryl, aryl, aralkyl, arylalkenyl, arylalkynyl, and cycloalkylalkylamino;

R<sub>11</sub> is selected from the group consisting of hydrogen, optionally substituted alkyl, and an alkalimetal; and

wherein said compound is <sup>3</sup>H or <sup>14</sup>C radiolabeled.

27. (New) The method according to claim 19, wherein the method is for treating, preventing or ameliorating neuronal loss following global or focal ischemia, treating or ameliorating neurodegenerative conditions, treating, preventing or ameliorating pain or tinnitus, treating, preventing or ameliorating manic depression, providing local anesthesia, treating arrhytmias, or treating convulsions.

Coux